Tyra Biosciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Tyra Biosciences, Inc. (TYRA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $33.43 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- Tyra Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $32.10, a 152.96% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $12.69, a 36.33% decline year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $19.93, a 133.10% increase year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.55, a 25.97% decline year-over-year.
- Tyra Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $12.08, a 41.36% decline from fiscal 2024.
- Tyra Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $20.60, a 55.35% increase from fiscal 2023.
- Tyra Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $13.26, a 71.98% increase from fiscal 2022.
- Tyra Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $7.71, a 26.22% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.43 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $32.10 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $12.08 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $10.79 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $10.81 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $12.69 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $20.60 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $20.62 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $17.52 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $19.93 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $13.26 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $13.32 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $10.30 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $8.55 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $7.71 10-K · filed 2023-03-22 | |||
| 2022-09-30 | $7.67 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $8.57 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $11.55 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $10.45 10-K · filed 2022-03-03 | |||
| 2021-09-30 | $3.42 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |